[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fNow4z7l5iYOd_ioE9IFVnIyaLz5ZUqdE5WmacKAVHL4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"Skane University Hospital",[4],72,false,18,1,51444,0,60,[14,17,19,22,24,27,29,31],{"name":15,"count":16},"Chronic Pain",5,{"name":18,"count":16},"Mild Cognitive Impairment",{"name":20,"count":21},"Alzheimer Disease",4,{"name":23,"count":21},"Lewy Body Disease",{"name":25,"count":26},"Carpal Tunnel Syndrome",3,{"name":28,"count":26},"Diabetes",{"name":30,"count":26},"Mild Dementia",{"name":32,"count":26},"Frontotemporal Degeneration",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,70,88,115,133,158,183,209,244,272,297,321,347,365],{"intervention":43,"totalTrials":9,"cells":44},"LTOT 24 h\u002Fday",{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":51,"PHASE4":53,"NA":68},{"trials":46,"activeCount":11},[],{"trials":48,"activeCount":11},[],{"trials":50,"activeCount":11},[],{"trials":52,"activeCount":11},[],{"trials":54,"activeCount":11},[55],{"nctId":56,"briefTitle":57,"status":58,"phases":59,"primaryCompletion":60,"completion":61,"start":62,"enrollment":63,"conditions":64,"interventions":66},"NCT03441204","REgistry-based Treatment Duration and Mortality in Long-term OXygen Therapy (REDOX)","COMPLETED",[39],"2022-04-04","2023-04-04","2018-05-16",241,[65],"Chronic Respiratory Failure With Hypoxia",[43,67],"LTOT 15h\u002Fday",{"trials":69,"activeCount":11},[],{"intervention":67,"totalTrials":9,"cells":71},{"EARLY_PHASE1":72,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":80,"NA":86},{"trials":73,"activeCount":11},[],{"trials":75,"activeCount":11},[],{"trials":77,"activeCount":11},[],{"trials":79,"activeCount":11},[],{"trials":81,"activeCount":11},[82],{"nctId":56,"briefTitle":57,"status":58,"phases":83,"primaryCompletion":60,"completion":61,"start":62,"enrollment":63,"conditions":84,"interventions":85},[39],[65],[43,67],{"trials":87,"activeCount":11},[],{"intervention":89,"totalTrials":9,"cells":90},"pioglitazone",{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":99,"NA":113},{"trials":92,"activeCount":11},[],{"trials":94,"activeCount":11},[],{"trials":96,"activeCount":11},[],{"trials":98,"activeCount":11},[],{"trials":100,"activeCount":11},[101],{"nctId":102,"briefTitle":103,"status":58,"phases":104,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":111},"NCT00609856","Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes",[39],"2006-12","2004-04",36,[109,110],"Type 2 Diabetes","Secondary Drug Failure",[89,112],"insulin glargine",{"trials":114,"activeCount":11},[],{"intervention":112,"totalTrials":9,"cells":116},{"EARLY_PHASE1":117,"PHASE1":119,"PHASE2":121,"PHASE3":123,"PHASE4":125,"NA":131},{"trials":118,"activeCount":11},[],{"trials":120,"activeCount":11},[],{"trials":122,"activeCount":11},[],{"trials":124,"activeCount":11},[],{"trials":126,"activeCount":11},[127],{"nctId":102,"briefTitle":103,"status":58,"phases":128,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":129,"interventions":130},[39],[109,110],[89,112],{"trials":132,"activeCount":11},[],{"intervention":134,"totalTrials":9,"cells":135},"Adalimumab",{"EARLY_PHASE1":136,"PHASE1":138,"PHASE2":140,"PHASE3":142,"PHASE4":144,"NA":156},{"trials":137,"activeCount":11},[],{"trials":139,"activeCount":11},[],{"trials":141,"activeCount":11},[],{"trials":143,"activeCount":11},[],{"trials":145,"activeCount":11},[146],{"nctId":147,"briefTitle":148,"status":58,"phases":149,"primaryCompletion":150,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":155},"NCT01270087","The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.",[39],"2007-02","2005-05",14,[154],"Rheumatoid Arthritis",[134],{"trials":157,"activeCount":11},[],{"intervention":159,"totalTrials":9,"cells":160},"Atorvastatin",{"EARLY_PHASE1":161,"PHASE1":163,"PHASE2":165,"PHASE3":177,"PHASE4":179,"NA":181},{"trials":162,"activeCount":11},[],{"trials":164,"activeCount":11},[],{"trials":166,"activeCount":11},[167],{"nctId":168,"briefTitle":169,"status":58,"phases":170,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":176},"NCT00454545","Atorvastatin in Moderate Active Crohns Disease",[37],"2007-10","2006-10",12,[175],"Crohns Disease",[159],{"trials":178,"activeCount":11},[],{"trials":180,"activeCount":11},[],{"trials":182,"activeCount":11},[],{"intervention":184,"totalTrials":9,"cells":185},"FP187",{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":203,"PHASE4":205,"NA":207},{"trials":187,"activeCount":11},[],{"trials":189,"activeCount":11},[],{"trials":191,"activeCount":11},[192],{"nctId":193,"briefTitle":194,"status":195,"phases":196,"primaryCompletion":197,"completion":198,"start":199,"enrollment":11,"conditions":200,"interventions":202},"NCT02475304","Proof-of-concept Study of Forward Pharma (FP)187 in Patients With Mild\u002FModerate Psoriatic Arthritis","WITHDRAWN",[37],"2016-10","2017-06","2015-05",[201],"Psoriatic Arthritis",[184],{"trials":204,"activeCount":11},[],{"trials":206,"activeCount":11},[],{"trials":208,"activeCount":11},[],{"intervention":210,"totalTrials":211,"cells":212},"oxytocin",2,{"EARLY_PHASE1":213,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":230,"NA":232},{"trials":214,"activeCount":11},[215],{"nctId":216,"briefTitle":217,"status":58,"phases":218,"primaryCompletion":219,"completion":219,"start":220,"enrollment":173,"conditions":221,"interventions":223},"NCT00776360","The Effect of Oxytocin on the Gastric Emptying",[35],"2009-12","2008-12",[222],"Postprocedural Delayed Gastric Emptying",[210,210],{"trials":225,"activeCount":11},[],{"trials":227,"activeCount":11},[],{"trials":229,"activeCount":11},[],{"trials":231,"activeCount":11},[],{"trials":233,"activeCount":11},[234],{"nctId":235,"briefTitle":236,"status":58,"phases":237,"primaryCompletion":238,"completion":238,"start":239,"enrollment":152,"conditions":240,"interventions":243},"NCT01152047","The Effect of Oxytocin on Gastric Emptying",[40],"2015-04","2010-05",[241,242],"Dyspepsia","Lack of Satiety",[210],{"intervention":245,"totalTrials":9,"cells":246},"Convalescent plasma",{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":255,"NA":257},{"trials":248,"activeCount":11},[],{"trials":250,"activeCount":11},[],{"trials":252,"activeCount":11},[],{"trials":254,"activeCount":11},[],{"trials":256,"activeCount":11},[],{"trials":258,"activeCount":11},[259],{"nctId":260,"briefTitle":261,"status":262,"phases":263,"primaryCompletion":264,"completion":265,"start":266,"enrollment":267,"conditions":268,"interventions":271},"NCT04600440","Convalescent Plasma in the Treatment of Covid-19","UNKNOWN",[40],"2021-12-31","2022-02-28","2020-04-25",100,[269,270],"Covid-19","Respiratory Insufficiency",[245],{"intervention":273,"totalTrials":9,"cells":274},"VWF\u002FFVIII products",{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":281,"PHASE4":283,"NA":285},{"trials":276,"activeCount":11},[],{"trials":278,"activeCount":11},[],{"trials":280,"activeCount":11},[],{"trials":282,"activeCount":11},[],{"trials":284,"activeCount":11},[],{"trials":286,"activeCount":11},[287],{"nctId":288,"briefTitle":289,"status":58,"phases":290,"primaryCompletion":291,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":296},"NCT00557908","The Von Willebrand Disease (VWD) International Prophylaxis Study",[],"2013-02","2007-06",105,[295],"Von Willebrand Disease",[273],{"intervention":298,"totalTrials":9,"cells":299},"FEIBA and NovoSeven",{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":306,"PHASE4":308,"NA":310},{"trials":301,"activeCount":11},[],{"trials":303,"activeCount":11},[],{"trials":305,"activeCount":11},[],{"trials":307,"activeCount":11},[],{"trials":309,"activeCount":11},[],{"trials":311,"activeCount":11},[312],{"nctId":313,"briefTitle":314,"status":58,"phases":315,"completion":316,"start":317,"enrollment":12,"conditions":318,"interventions":320},"NCT00166309","The FEIBA NovoSeven Comparative Study",[40],"2005-06","2000-07",[319],"Severe Hemophilia A With an Inhibitor",[298],{"intervention":322,"totalTrials":9,"cells":323},"polyethylene glycol",{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":325,"activeCount":11},[],{"trials":327,"activeCount":11},[],{"trials":329,"activeCount":11},[],{"trials":331,"activeCount":11},[],{"trials":333,"activeCount":11},[],{"trials":335,"activeCount":11},[336],{"nctId":337,"briefTitle":338,"status":58,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":345},"NCT02009202","Preparation Prior to Colonoscopy in Children",[40],"2014-06","2012-11",71,[344],"Inflammatory Bowel Diseases",[322,346],"picosulphate",{"intervention":346,"totalTrials":9,"cells":348},{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":357,"NA":359},{"trials":350,"activeCount":11},[],{"trials":352,"activeCount":11},[],{"trials":354,"activeCount":11},[],{"trials":356,"activeCount":11},[],{"trials":358,"activeCount":11},[],{"trials":360,"activeCount":11},[361],{"nctId":337,"briefTitle":338,"status":58,"phases":362,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":363,"interventions":364},[40],[344],[322,346],{"intervention":366,"totalTrials":9,"cells":367},"Paclitaxel",{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":374,"PHASE4":376,"NA":378},{"trials":369,"activeCount":11},[],{"trials":371,"activeCount":11},[],{"trials":373,"activeCount":11},[],{"trials":375,"activeCount":11},[],{"trials":377,"activeCount":11},[],{"trials":379,"activeCount":11},[380],{"nctId":381,"briefTitle":382,"status":58,"phases":383,"primaryCompletion":384,"completion":385,"start":386,"enrollment":387,"conditions":388,"interventions":391},"NCT05173857","Drug Eluting Balloon (DEB) vs Plain Old Balloon Angioplasty (POBA) in the Treatment of Failing Dialysis Access",[40],"2017-07-31","2018-07-31","2014-03-01",42,[389,390],"Vascular Diseases","Kidney Diseases",[366]]